消炎利胆片联合诺氟沙星胶囊治疗慢性胆囊炎的临床效果及安全性分析  

Clinical effect and safety analysis of Xiaoyan Lidan tablet combined with Norfloxacin capsule in the treatment of chronic cholecystitis

作　　者：陈志豪 Chen Zhihao(Changsha Central Hospital Affiliated to Nanhua University,Changsha,Hunan 410004,China)

机构地区：[1]南华大学附属长沙中心医院,湖南长沙410004

出　　处：《首都食品与医药》2023年第22期49-51,共3页Capital Food Medicine

摘　　要：目的探讨分析联合应用消炎利胆片+诺氟沙星胶囊治疗慢性胆囊炎的临床效果以及安全性。方法选取南华大学附属长沙中心医院收治的96例慢性胆囊炎患者,选取时间范围为2020年8月-2022年8月,采用抽签法等分为两组,每组各48例。参照组单纯应用诺氟沙星胶囊治疗,综合组则采用联合治疗方案(消炎利胆片+诺氟沙星胶囊)治疗。比对两组的疗效、肝胆功能指标、血清生化指标、炎性因子水平、不良反应发生率。结果综合组治疗效果要优于参照组,组间数据差异有统计学意义(P<0.05)。两组治疗后的AST、ALT水平以及胆囊壁厚度均要低于治疗前,且综合组低于参照组,数据差异具有统计学意义(P<0.05)。两组治疗后的胆红素、总胆汁酸水平组间对比无统计学差异(P>0.05);而综合组的总胆固醇、hs-CRP、TNF-α水平均要低于参照组,数据有显著差异(P<0.05)。且两组不良反应总发生率组间对比无统计学差异(P>0.05)。结论对慢性胆囊炎患者采用联合治疗方案(消炎利胆片+诺氟沙星胶囊)干预,可取得显著疗效,有效改善患者的肝胆功能,减轻患者炎症反应,且不会提高患者的不良反应发生率,具有较高的安全性。Objective To explore and analyze the clinical effect and safety of combined application of Xiaoyan Lidan tablets and norfloxacin capsules in the treatment of chronic cholecystitis.Methods 96 patients with chronic cholecystitis were selected from August 2020 to August 2022 and divided into two groups with 48 cases in each group by drawing lots.The reference group was treated with norfloxacin capsules alone,and the comprehensive group was treated with the combination therapy(anti-inflammatory gallbladder tablets+norfloxacin capsules).The therapeutic effect,liver and bile function index,serum biochemical index,inflammatory factor level and incidence of adverse reactions were compared between the two groups.Results The treatment effect of the comprehensive group was better than that of the reference group,and the difference between groups was statistically significant(P<0.05).The levels of AST,ALT and gallbladder wall thickness after treatment were lower than before treatment,and the comprehensive group was lower than the reference group,the data differences were statistically significant(P<0.05).There were no significant differences in the levels of bilirubin and total bile acid between the two groups after treatment(P>0.05).The levels of total cholesterol,hs-CRP and TNF-αin the comprehensive group were lower than those in the reference group,with significant differences(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with chronic cholecystitis,the combined treatment regimen(Xiaoyan Lidan tablet+norfloxacin capsule)can achieve significant efficacy,effectively improve the liver and bile function of patients,reduce the inflammatory response of patients,and will not increase the incidence of adverse reactions in patients,with high safety.

关 键 词：慢性胆囊炎 消炎利胆片 诺氟沙星胶囊 疗效 

分 类 号：R575.61[医药卫生—消化系统]